Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • 6 May 2014

    ACG's Pithampur Factory Awarded Gold Rating by LEED-India; First in Pharma Industry to Receive the Certification

    (PRNewswire; 6th May, 2014); ACG's continued commitment towards sustainability and efforts in building sustainable sites, reducing water and energy consumption, recycling building material and improving indoor environmental quality has now been recognized. Indian Green Building Council (IGBC) LEED®-India has awarded its prestigious Gold rating to ACG's new state-of-the-art capsule manufacturing plant in Pithampur, making it the first factory in Indian pharmaceutical industry to receive this rating.

  • 6 May 2014
    Eczema may reduce risk of skin cancer

    (6th May, 2014);As per new findings by investigators from King’s College London, Eczema caused by defects in the skin could reduce the risk of developing skin cancer. The immune response generated by eczema could help prevent tumour formation by shedding potentially cancerous cells from the skin.

  • 2 May 2014
    Researchers made Sperm Cells from Skin of infertile men

    (2nd May, 2014); Team of researchers from Montana State University showing that skin cells from infertile man can be used to create, primary germ cells - precursors of sperm. This research is providing ray of hope for future treatment of male infertility.

  • 1 May 2014
    ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia

    (1st May, 2014); At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migraine. The first poster presentation, on April 28th, found that two hours after treatment with electroCore’s nVNS therapy patients who had both chronic migraine and medication overuse headache were pain free in 33% of attacks while significant pain relief (mild or no pain) was noted in 50% of attacks. In the second poster presented on May1st it was found that 45 % of patients, with migraine without aura, were pain free within 30 minutes of just one dose of nVNS therapy.

  • 30 April 2014
    Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

    (30th Apr, 2014);Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

  • 28 April 2014
    DTAB concern about wide variation in the quality of Generic Drugs

    (28th Apr, 2014); In their last meeting, Drugs Technical Advisory Board (DTAB) raised the issue of wide variation in the quality of generic drugs manufactured in the country by small scale sector. The generic medicines of lower quality have not been found effective in patients.

  • 28 April 2014
    Continued USFDA approval for oral dosage facility in Strides Arcolab

    (28th April, 2014); Strides Arcolab announced on 25th April that its Oral Dosage Forms  manufacturing site (KRS Gardens) in Bangalore was recently inspected by the USFDA as part of  GMP compliance audit and the facility continues to be approved.

  • 24 April 2014
    Portfolio transformation between Pharma Giants - GlaxoSmithKline, Novartis & Lilly

    (24th Apr, 2014); Now Novartis will focus more on oncology business, GlaxoSmithKline will focus on vaccines business and Lilly to concentrate more on Animal Health Division, concluded from portfolio transformation deals between said companies.

  • 22 April 2014
    Shiseido Opens Research Facility Dedicated to Hair Regeneration

    Shiseido Co., Ltd. announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.

  • 18 April 2014
    ICMR releases consensus document for management of Esophageal Cancer

    Indian Council of Medical research (ICMR) releases consensus document for management of esophageal cancer (EC), prepared as an outcome of ICMR Subcommittee on EC.

Subscribe to Pharma News